1548 — Genscript Biotech Balance Sheet
0.000.00%
- HK$28.90bn
- HK$23.34bn
- $594.49m
- 30
- 26
- 96
- 50
Annual balance sheet for Genscript Biotech, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 771 | 1,403 | 1,463 | 1,928 | 621 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 166 | 167 | 171 | 300 | 136 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 993 | 1,639 | 1,765 | 2,353 | 835 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 385 | 505 | 647 | 751 | 603 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,447 | 2,234 | 2,546 | 3,387 | 5,278 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 328 | 413 | 546 | 495 | 307 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 546 | 1,188 | 1,536 | 1,996 | 957 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 902 | 1,046 | 1,011 | 1,391 | 4,321 |
| Total Liabilities & Shareholders' Equity | 1,447 | 2,234 | 2,546 | 3,387 | 5,278 |
| Total Common Shares Outstanding |